It exerts its anti-tumor effects by binding to EGFR and c-MET (56) on the tumor surface, thereby inhibiting the activation of their signaling pathways and binding to extracellular segments to promote receptor-antibody complex degradation (71). The gene discussed is MET; the disease is neoplasm.